Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis

BACKGROUND: Adjuvant chemotherapy (ACT) is routinely the recommended treatment for patients with advanced non-small cell lung cancer (NSCLC) but remains a controversial option in stage IB patients. We therefore pooled the current evidence to determine the prognostic impact of ACT in stage IB NSCLC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Xiaofan, Chen, Donglai, Wen, Junmiao, Mao, Yiming, Zhu, Xuejuan, Fan, Min, Chen, Yongbing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506786/
https://www.ncbi.nlm.nih.gov/pubmed/34733982
http://dx.doi.org/10.21037/atm-21-4001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506786/
https://www.ncbi.nlm.nih.gov/pubmed/34733982
http://dx.doi.org/10.21037/atm-21-4001

Ejemplares similares